SCHEMBL30837012

SCHEMBL30837012

CCSc1ccc(Nc2ncc3cc(Cl)c(=O)n(C4CCCC4)c3n2)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 17/20 0.51
CDK2 P24941 13/20 0.51
CDK4 P11802 12/20 0.51
CCNE1 P24864 7/20 0.51
CDK6 Q00534 7/20 0.51
CCND3 P30281 4/20 0.51
CCNT1 O60563 2/20 0.51
CDK9 P50750 2/20 0.51
PRKDC P78527 2/20 0.47
TTK P33981 2/20 0.47
CSF1R P07333 1/20 0.47
CCNA2 P20248 6/20 0.46
FGFR1 P11362 5/20 0.46
FGFR2 P21802 5/20 0.46
FGFR4 P22455 5/20 0.46
FGFR3 P22607 5/20 0.46
CCND2 P30279 3/20 0.45
CCNA1 P78396 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27229160 1.00 CCND1 (0.51) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27362368 0.85 CCND1 (0.50) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27370551 0.84 CCND1 (0.47) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27358626 0.84 CCND1 (0.54) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27358400 0.83 CCND1 (0.50) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27357550 0.83 CCND1 (0.49) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL25122544 0.82 CDK2 (0.59) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL29990907 0.82 CDK2 (0.57) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL25122980 0.82 CDK2 (0.57) CCND1CDK2CDK4CCNE1CDK6
SCHEMBL27358622 0.82 CDK2 (0.53) CCND1CDK2CDK4CCNE1CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573094-A2 CDK2 INHIBITORS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-06-25 EP disclosed
WO-2024039903-A2 CDK2 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-02-22 WO disclosed